TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Latiglutenase as a Treatment for Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy confirmed CD diagnosis~* Self-reported adherence to a gluten-free diet for ≥ 12 months~* Agree to maintain dosing of approved prescribed and OTC medications~* Willing to take study treatment with evening meal during any single day~* Willing to take gluten foodstuff with evening meal during any single day~* Willing to maintain GFD for entire study duration~* Willing to agree to minimal ingestion outside of three main daily meals~* Willing and able to comply with all study procedures~* Access to the internet via smartphone, tablet, computer or equivalent to facilitate daily symptom reporting~* Must sign informed consent~Exclusion Criteria:~* Active dermatitis herpetiformis at the time of screening~* IBS (Irritable Bowel Syndrome)~* History of any form of colitis~* Received any systemic biologics (such as monoclonal antibodies or other protein therapeutics where the half-life overlaps with the study start) within 6 months prior to study start~* Taking any oral probiotic supplements (not including probiotics contained in commercially available food preparations) 6 months prior to entry~* Use of any immunosuppressive medications (i.e., for chronic treatment of autoimmune disease or transplant-rejection prophylaxis) 6 months prior to entry~* History of alcohol abuse, illegal drug use~* Unwilling to practice highly effective birth control (unless surgically sterilized or post-menopausal)~* Received any experimental drug within 30 days of randomization, in the case of experimental biologics at least 6 months prior to randomization~* Uncontrolled complications of celiac disease, which, in the opinion of the investigator, could affect immune response or pose an increased risk to the patient~* Inability to give informed consent~* Any medical condition, other than celiac disease, which, in the opinion of the investigator, could adversely affect the patient's participation in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Latiglutenase (Type: ACTIVE_COMPARATOR): IMGX003
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Obstructive Sleep Apnea in Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant Females~  1. 18 years of age and older~ 2. scheduled induction of labor~ 3. spontaneously laboring~ 4. scheduled cesarean delivery~* Nonpregnant Females~  1. 18 years of age or older~ 2. presenting to the PWH OR for gynecologic surgery~ 3. presenting to the NMH Ambulatory Surgery Center for ambulatory surgery~Exclusion Criteria:~* patient refusal~* patient age \> 45 years old~* inability to understand the English language~* patient presenting for an emergency procedure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Pregnant population (Type: None): The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
- Non-Pregnant Population (Type: None): The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: QP ExCELs: MultiPole Pacing (MPP) Sub-Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently enrolled in the ongoing QP ExCELs study~* Successfully implanted with a BIOTRONIK Ilivia 7 HF-T QP family CRT-D system, or future-marketed CRT-D system with the MPP feature. Successful implantation is defined as having at least two LV pacing vectors with a measured pacing threshold of ≤ 5.0 V @ any pulse width (allowing for a minimum 2.5 V safety margin) without phrenic nerve stimulation at the final programmed pacing output at the time of enrollment into the MPP sub-study.~* CRT Responder Assessment classification as Worsened or Unchanged~* Standard continuous biventricular (BiV) pacing from implant until the 6-Month QP ExCELs follow-up visit. (Implant to 3-Month QP ExCELs follow-up who qualify due to a Heart Failure (HF) hospitalization event)~* Able to understand the nature of the sub-study and give informed consent~* Available for an additional follow-up visit specific to the MPP sub-study at the investigational site~* No evidence of non-compliance to their ongoing commitment in the QP ExCELs study~Exclusion Criteria:~* Have a life expectancy of less than 6 months~* Expected to receive heart transplantation or ventricular assist device within 6 months~* Chronic atrial fibrillation~* Presence of another life-threatening, underlying illness separate from their cardiac disorder~* Received MPP pacing prior to enrolment into the MPP sub-study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MultiPole Pacing (Type: EXPERIMENTAL): Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Gastric Reduction for Weight Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) between 30 and 40~* Age \>18 and ≤50~* Stable weight for 3 months (within 5% of BMI)~* Normal basic labs (CBC, chemistry profile, creatinine)~* Negative pregnancy test for females \>18 or ≤ 50~Exclusion Criteria:~* Diabetes~* Unstable coronary artery disease~* Heart failure~* Cardiac arrhythmia~* Cardiac valvular disease~* Obstructive of interstitial lung disease~* Females of child-bearing age \>18 or ≤ 50 who are pregnant or lactating~* Mallampati score of 4~* ASA 3 or above~* Previous gastric surgery~* Ulcer disease~* Gastroparesis,~* \> 5 cm Hiatal hernia~* Congenital anomalies of the GI tract~* Currently on or prescribed a medication known to affect weight within 3 months of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin at injection site (Type: EXPERIMENTAL): All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening~* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)~* Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 \< 0.1 μM~* Cluster of differentiation (CD)4+ T-cell count \> 50 cells/mm3~Exclusion Criteria:~* History (or evidence at Screening) of genotypic resistance to any component of the study regimen \[ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)\]~* Certain laboratory and electrocardiogram (ECG) values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 1
- Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 2
- Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 3
- Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 4
- Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir (Type: ACTIVE_COMPARATOR): Treatment Group 1 (reference arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
In India:~Inclusion Criteria:~1. Age ≥ 5 years, male or female for IDA arm and age \> 2 years for DA arm.~2. Able to provide informed consent to participate in the trial (forms to be attached)~3. No evidence of severe or systemic co-morbidities except for features of filarial disease~Exclusion Criteria:~1. Age \< 5 years (ivermectin is contraindicated in children below 5 years of age) for IDA arm and age \< 2 years for DA arm~2. Pregnant women (DEC, ivermectin and albendazole are contraindicated in pregnancy)~3. Severe chronic illness (for example, chronic renal failure, inability to care for oneself with activities of daily living)~4. History of previous allergy to MDA drugs~For rest of countries:~Inclusion Criteria:~1. Age ≥ 5 years, for IDA and DA arms (males and females).~2. Able to provide informed consent or give parental consent for minors to participate in the trial~3. No evidence of severe or systemic co-morbidities except for features of filarial disease~Exclusion Criteria:~1. Age \< 5 years (ivermectin is not approved for use in children less than 5 years of age)~2. Unable to provide informed consent or give parental consent for minors to participate in the trial~3. Pregnant women (DEC, ivermectin and albendazole are not known to be safe for use during pregnancy)~4. Severe chronic illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living)~5. History of previous allergy to MDA drugs

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2 drug dose - DA (Type: ACTIVE_COMPARATOR): Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
- 3 drug dose - IDA (Type: EXPERIMENTAL): Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients aged 18-80 years with American Society of Anesthesiologist (ASA) classification I-III undergoing cervical spine surgery in the prone position with intraoperative motor evoked potential monitoring.~* Operation time greater than 3 hours~Exclusion Criteria:~* Allergy to propofol or documented egg allergy~* Known allergy to sugammadex~* Severe renal dysfunction (EGFR\<30)~* British Research Medical Council (BRMC) motor grading \<3 in any peripheral muscle group preoperatively. This is inability to move the muscle group against gravity.~* Surgical requirement of strict muscle relaxation for surgical exposure~* Lack of informed consent~* Pregnancy~* Loss of MEP signals during washout period (or intraoperative spinal cord injury resulting in irreversible loss of MEP)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Initial Arm (Type: ACTIVE_COMPARATOR): The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
- Crossover Arm (Type: ACTIVE_COMPARATOR): The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age of 25 + 0 to 32 + 0 weeks PMA at birth, and 34 + 0 to 375 + 6 weeks PMA at randomization~2. Prior treatment with caffeine based on routine clinical indications, and clinical caffeine now discontinued ≥5 days before randomization~3. Previously tolerated clinical treatment with caffeine~4. Breathing room air (no current supplemental O2 treatment; may have previously required respiratory support)~5. Parental consent to enroll in pilot study~Exclusion Criteria:~1. Congenital syndrome or other medical diagnosis associated with known risk for neurodevelopmental abnormality, including intraventricular hemorrhage Grade 3 or greater, cyanotic congenital heart disease, confirmed central nervous system infection, or fetal alcohol syndrome~2. Currently receiving supplemental oxygen, ventilatory support, or nasal airflow therapy~3. Clinical decision to restart caffeine prior to completing 5 days of continuous physiologic monitoring after clinical caffeine stopped~4. Anticipated inability to meet protocol requirements

- Gender: ALL
- Minimum Age: 33 Weeks
- Maximum Age: 37 Weeks
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: EXPERIMENTAL): Caffeine citrate 6 mg/kg/day
- Active Comparator: no caffeine (Type: NO_INTERVENTION): Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed lung cancer (Stage IIIb/IV nonsmall-cell lung cancer or extensive stage small-cell lung cancer \[SCLC\])~* Measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified World Health Organization criteria~* Eastern Cooperative Oncology Group performance status of ≤1 at study entry~* Accessible for treatment and follow-up~Exclusion Criteria:~* Brain metastases~* Malignant pleural effusion~* Autoimmune disease~* Motor neuropathy of autoimmune origin~* SCLC-related paraneoplastic syndromes~* Any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)~* Prior systemic therapy for lung cancer. Prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.~  * Grade 2 peripheral neuropathy (motor or sensory)~* Known HIV or hepatitis B or C infection~* Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). However, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.~* Inadequate hematologic function defined by an absolute neutrophil count \<1,500/mm\^3, a platelet count \<100,000/mm\^3, or hemoglobin level \<9 g/dL.~* Inadequate hepatic function defined by a total bilirubin level \>2.0 times the upper limit of normal (ULN), or ≥2.5 times the ULN if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the ULN or ≥5 times the ULN if liver metastases are present.~* Inadequate renal function defined by a serum creatinine level ≥2.5 times the ULN~* Inadequate creatinine clearance defined as less than 50 mL/min.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent) (Type: EXPERIMENTAL): None
- Ipilimumab/ placebo + paclitaxel + carboplatin (sequential) (Type: EXPERIMENTAL): None
- Ipilimumab placebo + paclitaxel + carboplatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma~* Radiographic evidence of at least one bone metastasis (or lytic bone lesion from multiple myeloma); ECOG performance status 0, 1, or 2~* Adequate organ function~Exclusion Criteria:~* Diagnosis of breast or prostate cancer~* Current or prior intravenous bisphosphonate administration~* Current or prior oral bisphosphonates for bone metastases, life expectancy of less than 6 months~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: ACTIVE_COMPARATOR): denosumab placebo with active zoledronic acid
- denosumab (Type: EXPERIMENTAL): active denosumab with zoledronic acid placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Black Widow Spider Antivenin for Patients With Systemic Latrodectism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe pain intensity measured using the visual analog scale (VAS score ≥ 40mm) at the start of screening phase (VAS 0)~* Diagnosis of latrodectism by the Investigator, with concurrence of diagnosis by a physician not directly involved with the study~* Moderate to severe pain intensity measured using the visual analog scale (VAS score ≥ 40mm) at Baseline (VAS 1)~Exclusion Criteria:~* Less than 10 years of age~* Presents to the emergency department of any healthcare facility greater than 24 hours after onset of symptoms~* Has a known (self-reported) hypersensitivity to fentanyl, morphine, diazepam, or equine serum~* History of significant cardiac, respiratory, hepatic or renal disease, psychiatric disorder or chronic pain syndrome that in the investigator's assessment would confound efficacy or safety endpoint assessment (e.g., a bite to the leg of a patient with reflex sympathetic dystrophy)~* History or suspected history or substance abuse~* Pregnant or breast-feeding~* Has a distracting injury with acute pain, or is unable to make a reliable self-report of pain intensity to pain relief based solely on the condition of interest~* Was already treated with Merck Antivenin Latrodectus Mactans for signs/symptoms related to the current widow spider bite~* Unable to provide a telephone number to be contacted for follow-up interviews on Days 2, 10, and 17 after discharge from the emergency department

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Analatro (Type: EXPERIMENTAL): Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
- Normal Saline Placebo (Type: PLACEBO_COMPARATOR): Normal Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete